Nuttapong Ngamphaiboon

Internal Medicine

123 Summer St
Worcester, MA 01608

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Distinct genomic landscape of colorectal signet ring cell carcinoma reveals frequent KMT2 family alterations and SMAD4 inactivation.

Distinct genomic landscape of colorectal signet ring cell carcinoma reveals frequent KMT2 family alterations and SMAD4 inactivation.

Journal: BMC cancer

Published: March 15, 2026

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Journal: BMJ oncology

Published: January 24, 2026

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Journal: Frontiers in oncology

Published: November 18, 2025

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.

Journal: Cancer medicine

Published: April 11, 2025

Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients.

Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients.

Journal: JCO global oncology

Published: January 08, 2025

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 16, 2024

Predictive MINT Pathologic Risk Score for Adjuvant Chemotherapy in Resected Cholangiocarcinoma: A Propensity Score-Matched Multicenter Study in Thailand.

Predictive MINT Pathologic Risk Score for Adjuvant Chemotherapy in Resected Cholangiocarcinoma: A Propensity Score-Matched Multicenter Study in Thailand.

Journal: JCO global oncology

Published: October 17, 2024

Postoperative Radiation With or Without Concurrent Chemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma With Multiple Intermediate Risks: A Propensity Score-Matched Study.

Postoperative Radiation With or Without Concurrent Chemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma With Multiple Intermediate Risks: A Propensity Score-Matched Study.

Journal: Cancer medicine

Published: September 02, 2024

EPHX1 and ERCC2 polymorphisms are associated with cisplatin-induced nephrotoxicity and prognosis in Thai cancer patients.

EPHX1 and ERCC2 polymorphisms are associated with cisplatin-induced nephrotoxicity and prognosis in Thai cancer patients.

Journal: PloS one

Published: May 24, 2024

Development and Internal Validation of a Prediction Model for Nasopharyngeal Carcinoma: Using BMI and Inflammatory Response for Deciding Sequence of Chemotherapy.

Development and Internal Validation of a Prediction Model for Nasopharyngeal Carcinoma: Using BMI and Inflammatory Response for Deciding Sequence of Chemotherapy.

Journal: JCO global oncology

Published: February 15, 2024

Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.

Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.

Journal: Cancer medicine

Published: November 04, 2023

A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.

A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 01, 2023

Showing 1-12 of 50

Last Updated: 09/26/2026